Boehringer Ingelheim has become the latest company to enter the growing market of tumour agnostic medicines with the first KRAS inhibitor. …
Boehringer Ingelheim looking to bring tumour-agnostic trials to Australia
October 31, 2019 Latest News
Latest Video
New Stories
-
Sanofi treatment for ultra-rare ASMD made available through LSDP
October 22, 2025 - - Latest News -
Sigma reports strong growth and upgraded synergies in first full year post-merger
October 22, 2025 - - Latest News -
The mirage of US pharmaceutical pricing and how it could obscure the impact of 'MFN'
October 22, 2025 - - Latest News -
IDT Australia sharpens strategy with cost savings and radiopharmaceutical focus
October 21, 2025 - - Latest News -
FOI reforms set back transparency decades and will impact public health decision-making
October 21, 2025 - - Latest News -
Astellas' XTANDI achieves landmark survival milestone in prostate cancer
October 21, 2025 - - Latest News -
Services Australia reports record number of processed PBS prescriptions
October 21, 2025 - - Latest News